{rfName}

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Mauro, EzequielCorresponding AuthorSauri, TamaraAuthorIserte, GemmaAuthorFuster-Anglada, CarlaAuthorDiaz AAuthorDiaz, AlbaAuthorSererols-Vinas, LauraAuthorAffò, SilviaAuthorForner, AlejandroCorresponding Author

Share

August 4, 2024
Publications
>
Review

Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies

Publicated to: Current Oncology. 31 (7): 3615-3629 - 2024-07-01 31(7), DOI: 10.3390/curroncol31070266

Authors:

Ros-Buxo, Mar; Mauro, Ezequiel; Sauri, Tamara; Iserte, Gemma; Fuster-Anglada, Carla; Diaz, Alba; Sererols-Vinas, Laura; Affo, Silvia; Forner, Alejandro
[+]

Affiliations

Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid 28029, Spain - Author
Hosp Clin Barcelona, CDB, Pathol Dept, Barcelona Clin Liver Canc BCLC Grp, Barcelona 08036, Spain - Author
Hosp Clin Barcelona, Inst Clin Malalties Digest & Metab ICMDM, Barcelona Clin Liver Canc BCLC Grp, Liver Unit, Barcelona 08036, Spain - Author
IDIBAPS, Hosp Clin Barcelona, Barcelona Clin Liver Canc BCLC Grp, Inst Canc & Malaltiesde Sang ICAMS,Med Oncol Dept,, Barcelona 08036, Spain - Author
Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona 08036, Spain - Author
Univ Barcelona, Sch Med, 08007 Barcelona, Spain - Author
See more

Abstract

Biliary tract cancers (BTCs) are rare and aggressive malignancies with an increasing incidence and poor prognosis. The standard systemic treatment for BTCs has evolved to include immune checkpoint inhibitors associated with gemcitabine-cisplatin as first-line therapies. However, survival rates remain low, highlighting the critical need for personalized treatment strategies based on molecular profiling. Currently, significant advancements have been made in the molecular characterization of BTCs, where genetic alterations, such as IDH1 mutations and FGFR2 fusions, provide targets for therapy. Molecular profiling is crucial early in the management process to identify potential candidates for clinical trials and guide treatment strategy. The integration of these molecular insights into clinical practice has allowed for the development of targeted therapies, although many of them are still in the phase 2 trial stage without definitive survival benefits demonstrated in phase 3 trials. This integration of comprehensive molecular profile insights with traditional treatment approaches offers a new horizon in the personalized medicine landscape for BTCs, with the aim of significantly improving patient outcomes through precision oncology.
[+]

Keywords

Bile duct carcinomaBiliary tract cancerBiliary tract neoplasmsBiliary tract tumorBrafBtcChemotherapCholangiocarcinomaCisplatinClinical practiceCohort analysisDrug therapyEfficacyEscatFgfr2Fibroblast growth factor receptor 2First-line treatmentGemcitabineGeneticsHumanHumansIdh1Immune checkpoint inhibitorKrasLiver transplantatioLiver transplantationMetastatic cholangiocarcinomaMolecular fingerprintingMolecular profileMolecular targeted therapyMolecularly targeted therapyMulticenterNtrkOpen-labelPersonalized cancer therapyPersonalized medicinePhase 1/2Phase 2 clinical trialPlus gemcitabinePositive solid tumorsPrecision medicineProceduresReviewSingle-armSurvival rateSystemic therapyTherapyTreatment outcome

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Current Oncology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 118/328, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Oncology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 1
  • Scopus: 1
  • Europe PMC: 1
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 9.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 8 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 3.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Forner González, Alejandro).

the authors responsible for correspondence tasks have been Mauro, Ezequiel Matías and Forner González, Alejandro.

[+]

Awards linked to the item

E.M. received the Andrew K. Burroughs Short-Term Training Fellowship 2021 from EILF-EASL. G.I. received grant support from the Asociacion Espanola para el Estudio del Higado (Beca de Enfermeria) and the Societat Catalana de Digestologia. C.F.-A. received the Research Hospital Clinic's contract "Emili Letang-Josep Font 2020". A.D. received grant support from the Instituto de Salud Carlos III (PI18/01125). S.A. is supported by PID2021-124694OA-I00 financed by MCIN/AEI/10.13039/501100011033 and by "FEDER Una manera de hacer Europa". A.F. received a grant from the Instituto de Salud Carlos III (PI15/01229 and PI18/00542). CIBERehd is funded by the Instituto de Salud Carlos III. Some of the authors of this article are members of the European Reference Network (ERN) RARE-LIVER, the European Network for the Study of Cholangiocarcinoma (ENS-CCA), and participate in the COST Action Precision-BTC-Network CA22125, supported by COST (European Cooperation in Science and Technology; www.cost.eu).
[+]